If this assessment is correct, the contrasting effects of losartan in relatively similar genetic models of muscle disease (DMD and LGMD2B) suggests that caution must be taken when testing experimental therapies in animal models harbouring mutations of the dystrophin-associated glycoprotein complex. Here, DMD is linked to Duchenne muscular dystrophy.